INTRODUCTION {#s1}
============

Atrial fibrillation (AF) is the most common form of chronic arrhythmia, with increasing health care burden and the mainly complications of atrial fibrillation are stroke and heart failure. Various studies had demonstrated that AF progression from the paroxysmal atrial fibrillation (PAF) to more sustained forms, and recurrence could increase morbidity and mortality. AF patients with progression have more adverse cardiovascular events and are more often admitted in the hospital \[[@R1]\]. The higher HATCH (hypertension, age \> 75 years, previous transient ischemic attack or stroke chronic obstructive pulmonary disease, heart failure) scores correlate with higher occurrence of AF and a high risk for stroke, which can be used as a selection criteria for intensified Electrocardiograph monitoring \[[@R2]\].

Chronic obstructive pulmonary disease (COPD) is a major public health problem and is characterized by non-reversible airflow limitation. COPD is not only an independent predictor for major adverse cardiac events but also a predictor of AF incidence \[[@R3], [@R4]\]. The rate of AF incident was inversely associated with forced expiratory volume in one second (FEV1). AF prevalence was higher in severe airflow obstruction subject than those with mild or moderate airflow obstruction \[[@R5], [@R6]\]. Moreover, the risk of AF hospitalization was higher among the lower FEV1, especially for FEV1 \< 60% \[[@R7]\]. Previous Studies have reported that the major cause of deaths in COPD patients is cardiovascular diseases (CVD) rather than respiratory failure and it is more likely to develop acute coronary syndrome and heart failure. Furthermore, COPD contributes most to the increased all-cause mortality of AF \[[@R8]\].

Various mechanisms about the association between AF and COPD had been widely explored. Oxidative stress and chronic systemic inflammation play vital roles in the pathology of COPD, resulting in atrial myocyte breakdown and fibrosis, and as a consequence progress to AF initiation and maintenance. Glycogen accumulation and atrial fibrosis are proved be risk factors for AF progression in animal models \[[@R9]\]. In the hypoxia condition among the COPD patients, matrix metalloproteinases expression increase which is a important molecular for the regulation of atrial structural remodeling \[[@R10]\]. Hypoxia can cause the constriction of pulmonary arteriolar gradually resulting in the pulmonary hypertension. Higher PaCO2 values and higher pulmonary artery systolic pressure (PASP) value significantly raise the AF prevalence \[[@R11]\]. Furthermore, low potassium is one of most common electrolyte disturbances in COPD, which might be caused by the use of corticosteroids or beta-blockers. The serum potassium level can influence the cell membrane potential. Low serum potassium increases the p-wave duration which is also a predictor for the incidence of AF \[[@R12]\].

Pulmonary hypertension can contribute to right atrial (RA) hemodynamic overloading or stretching, resulting in the prevalence of non-pulmonary vein (PV) foci in the COPD patients \[[@R9]\]. Commonly, most PAF originate from the pulmonary veins (PVs).There are still some other originations in the non-PV foci such as the superior vena cava (SVC), left atrial free wall (LAFW), crista terminalis (CT), coronary sinus ostium, ligament of Marshall, left atrial appendage, and interatrial septum which have been proved to be a risk factor for AF progression and recurrence. Among these patients the non-PV triggers could not be incompletely eliminated. Moreover, the RA conduction time is prolonged with COPD and the prevalence of typical atrial flutter recurrence increases positively with the severity of COPD, regardless of effective therapies \[[@R13]\].

Although many traditional factors that cause heart structural remodeling such as hypertension, age, heart failure, diabetes can promote AF progression and recurrence, there is few data concerning the influence of COPD on progression and recurrence in all kinds of AF patients \[[@R14]\].

A wide range of methods including catheter ablation, pharmacological cardioversion, electrical cardioversion are used for the maintenance of sinus rhythm in AF patients. The AF recurrence and progression rates are still high causing a heavy economic burden. Therefore, the present systematic review and meta-analysis aims to investigate the role of predictor that COPD plays for AF.

MATERIALS AND METHODS {#s2}
=====================

Search strategy and criteria {#s2_1}
----------------------------

Firstly, we searched MEDLINE/PubMed, EMBASE and Cochrane databases and Web of Science. The following MeSH, full text and keyword terms: "atrial fibrillation" AND ("COPD" OR "chronic obstructive pulmonary disease" OR "Pulmonary Disease, Chronic Obstructive") were used to identify all the published articles in English. We excluded the trials published solely in abstract form because the results could not be fully analyzed.

Data extraction {#s2_2}
---------------

Two blinded reviewers (Xiaoying Chen and Meiling Lin) first screened independently the citations. The specific inclusion criteria were: (1) human studies, (2) the investigated patients are AF patients which was not developed after the CABG, (3) included the outcome of atrial progression and recurrence, (4) the mean follow-up of at least 6 months, (5) progression was defined as change from paroxysmal or persistent AF to a more sustained form, (6) recurrences were defined as episodes of AF or atypical atrial flutter or atrial tachycardia lasting at least 30s detected during follow-up at least after 6 months. Exclusion criteria: (1) non-human studies, (2) studies including patients undergoing CABG atrial fibrillation, (3) valvar atrial fibrillation.

Statistical analysis {#s2_3}
--------------------

Since none of the included studies was random control trail, we assessed risk of bias using the Newcastle-Ottawa scale. The pooled Odds ratio and 95% confidence intervals were calculated using the Mantel-Haenszel method. A fixed-effect model was used if the trials were similar, and a random-effects model was used if they varied. The numbers with progression or recurrence were calculated. Plot analysis was used to evaluate potential publication bias, and Cochran *Q*^2^ tests and I^2^ to investigate heterogeneity.

RESULTS {#s3}
=======

Search results {#s3_1}
--------------

The searching strategies in different database identified 962 abstracts (538 in PubMed/MEDLINE, 161 in Web of Science 173 in EMBASE, 90 In Cochrane library. Among them 895 were excluded according to the application of exclusion and inclusion criteria. 67 of them were selected and full text was read by two blinded authors. Among them, 2 were case reports and 3 were without data. 49 were excluded because of incomplete baseline, follow-up characteristics, or without the outcome of progression or recurrence. 4 were excluded because of reporting duplicate data and 2 because it was a case report. Following this selection approach, 7 trials were identified and finally 7 studies were included in the meta-analysis (Figure [1](#F1){ref-type="fig"}).

![Search criteria and flow graph of the studies screened and included in this meta-analysis](oncotarget-08-102420-g001){#F1}

Baseline patient characteristics {#s3_2}
--------------------------------

Our literature search identified 7 studies investigating the potential association between COPD and AF recurrence and progression despite of different cardioversion. A total of 10761 patients with AF were finally included from 7 studies.(1556 with AF and COPD, 9205 without COPD). Based on the 6 studies reporting this detail, 63.9% were paroxysmal AF, 22.8% persistent AF patients, 6.7% long-standing persistent AF and 5% first detected AF. Baseline characteristics are shown in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}. Mean age from each study ranged from 51 to 81 years, and 57.2% were male. Hypertension accounted for 75.5% of the population. And 20.7% had the comorbidity of diabetes mellitus (DM). The mean left atrial diameter was 43.3 mm, and mean BMI was 27.4 kg/m^2^. 4 studies provided specific therapy \[[@R13], [@R15]--[@R17]\]. Among them, 30.2% were treated with electrical cardioversion, 45.7% with antiarrhythmic drugs, and 24.4% with catheter ablation. As all the studies which were included in this analysis were prospective studies, the Newcastle Ottawa Scale (NOS) was used to assess the methodological quality of the studies. NOS assessment involved a minimum number of zero to a maximum number of 8 depending on the quality of the study being assessed. The results have been listed in Table [3](#T3){ref-type="table"}.

###### First author, publication date, population, and main characteristics of the included studies

  Author                         year   study design        Study population   Follow-up (months)   Number of patients   Mean age (years)   Male   Hypertension   DM
  ------------------------------ ------ ------------------- ------------------ -------------------- -------------------- ------------------ ------ -------------- ------
  Pisters, Ron \[[@R15]\]        2012   prospective study   1801               12                   1801                 64.1               1063   1149           304
  Okcun, B. \[[@R16]\]           2002   prospective study   173                6                    110                  69 ± 9             56     70             15
  Hayashi, Takekuni \[[@R13]\]   2013   prospective study   181                \> 6                 68                   64.5               54     N/A            N/A
  Gu, J. \[[@R17]\]              2013   prospective study   550                31.4 ± 4.8           550                  64.2               326    290            55
  de Vos, C. B. \[[@R19]\]       2010   prospective study   1219               12                   1219                 64 ± 13            695    752            182
  Holmqvist, F. \[[@R29]\]       2015   prospective study   6235               6                    6235                 74 (65--81)        3554   5113           1746
  Vidal-Perez, R. \[[@R24]\]     2013   prospective study   788                33.6 ± 8.4           788                  74.8 ± 9.2         413    595            192

DM. Diabetes Mellitus; N/A, no available.

###### Baseline characteristics of study population included

  Author              year   Mean AF duration (months)   Paroxysmal   persistent   long-standing   First detected   BMI (kg/m^2^)   Left atrial diameter (mm)   ECV   Drug   Catheter ablation
  ------------------- ------ --------------------------- ------------ ------------ --------------- ---------------- --------------- --------------------------- ----- ------ -------------------
  Pisters, Ron        2012   N/A                         631          653          no              493              27.8            44.2                        712   1098   no
  Okcun, B.           2002   89.1 ± 75.3                 N/A          N/A          N/A             N/A              N/A             N/A                         52    58     no
  Hayashi, Takekuni   2013   44.4 ± 56.3                 36           24           8               no               N/A             40.0 ± 7.4                  no    no     68
  Gu, J.              2013   59.1 ± 13.1                 191          189          170             no               24 ± 2.5        46.2 ± 3.2                  no    no     550
  de Vos, C. B.       2010   N/A                         1054         no           no              165              27 ± 4          43 ± 8                      N/A   N/A    N/A
  Holmqvist, F.       2015   42 (18--85)                 4739         1496         no              no               29 (25--34)     43 (38--48)                 N/A   N/A    N/A
  Vidal-Perez, R.     2013   73.2 ± 61.2                 106          55           529             88               30.1 ± 4.8      N/A                         N/A   N/A    N/A

N/A, no available; AF, atrial fibrillation; BMI, body mass index; ECV electrical cardioversion.

###### The Newcastle-Ottawa Scale (NOS) for assessing the quality of the studies

  Study                          Selection   Comparability   Outcome   Total                   
  ------------------------------ ----------- --------------- --------- ------- --- --- --- --- ---
  Pisters, Ron \[[@R15]\]        1           1               1         1       1   1   1   1   8
  Okcun, B \[[@R16]\]            1           1               1         1       1   1   1   1   8
  Hayashi, Takekuni \[[@R13]\]   1           1               1         1       1   1   1   1   8
  Gu, J \[[@R17]\]               1           1               1         1       1   1   1   1   8
  de Vos, C. B \[[@R19]\]        1           1               1         1       1   1   1   1   8
  Holmqvist, F \[[@R29]\]        1           1               1         1       1   1   1   1   8
  Vidal-Perez, R \[[@R24]\]      1           1               1         1       1   1   1   1   8

AF recurrence and progression associated with COPD {#s3_3}
--------------------------------------------------

As listed in Figure [2](#F2){ref-type="fig"}, the pool analysis showed that COPD could promote AF progression (OR = 1.90; 95% CI, 1.34--2.68, I^2^ = 77%, *p* = 0.0003). For subgroup analysis (Figure [3](#F3){ref-type="fig"}), we also found COPD could increase the risk of AF recurrence (OR = 2.35; 95% CI, 1.86--2.97, I^2^ = 0%, *p* = 0.39). Among all the included studies, in the younger ages, at the median age of 64, COPD was still a risk factor for AF progression (OR = 2.22; 95% CI, 1.80--2.74, I^2^ = 0%, *p* = 0.69). Analysis of publication bias was conducted. The funnel plots showed a low to moderate risk of publication bias across the studies based on a visual analysis (Figure [4](#F4){ref-type="fig"}).

![Forest plot on the association between COPD and atrial fibrillation recurrence and progression](oncotarget-08-102420-g002){#F2}

![Subgroup analysis: forest plot on the association between COPD and atrial fibrillation recurrence](oncotarget-08-102420-g003){#F3}

![Funnel plot to analyze publication bias](oncotarget-08-102420-g004){#F4}

DISCUSSION {#s4}
==========

COPD had been demonstrated increasing the risk of cardiac arrhythmia, especially for AF. AF patients with COPD often present more comorbid diseases, and at a higher risk of complications \[[@R18]\]. Among all the present studies concluded, the majority of classified deaths of AF are cardiovascular diseases, whereas non-hemorrhagic stroke or systemic embolism constitute a small part. A 12-year follow-up study had proved that AF progression could increase hospital admissions and major adverse cardiovascular events \[[@R19]\].

Besides, anticoagulation therapy can improve survival in these patients, whether new oral anticoagulation or vitamins k antagonist \[[@R20]\]. Despite the high prescription of oral anticoagulation (OAC), 1-year mortality and morbidity remain high in AF patients, particularly from heart failure and hospitalizations \[[@R21]\]. Moreover, anticoagulation treatment is inadequate in patients with AF and COPD \[[@R22]\]. It had been proved that COPD, cancer and chronic heart failure (CHF) were each associated with over 20% increased risk of OAC treatment discontinuation \[[@R20], [@R23]\].

COPD patients showed a higher trend to concomitant with structural heart disease. Our data conformed the positive association between AF progression and high mortality and morbidity \[[@R24]\]. COPD is also a vital risk factor for AF patients in terms major adverse cardiac events (MACE) including all-cause mortality, stroke, non-central nervous system systemic embolism and major bleed \[[@R25]\]. The cardiovascular and non-cardiovascular death were higher among AF patients with COPD \[[@R16]\]. However, there are no unanimous results about whether COPD could increase the risk of stroke or systemic embolism in AF patients. Some studies figured out that the presence of COPD might increase the occurrence of ischemic stroke in subjects with AF, while some other studies did not find \[[@R26], [@R27]\].

Actually, long-term SR maintenance is an effective treatment to reduce the risk of complications related to AF and the reasonable control of ventricular rate can increase the survival rate \[[@R28]\]. Many patients with PAF included in this study progressed to persistent or permanent AF, despite hard effect to maintain sinus rhythm \[[@R19]\]. The absence of COPD is a predictor of the maintenance of sinus rhythm after electrical cardioversion or pharmacological cardioversion whether it is oral or intravenous chemical cardioversion \[[@R15]\]. Higher heart rates and advanced ages are also strong predictors for AF progression from paroxysmal or persistent a more sustained form \[[@R29], [@R30]\].

Catheter ablation of AF is widely applied for patients with symptomatic AF. COPD can affect lung morphological alterations which will cause marked change in PV anatomy, increasing the risk of AF recurrence. Non-pulmonary vein foci in the right atrial are also common in AF patients with COPD. The present study confirmed that catheter ablation of AF is feasible and safe in COPD patients using Bispectral index (BIS) monitoring to ablation \[[@R31]\].

Catheter ablation of AF can reduce AF progression risk \[[@R32]\]. Sometimes, prophylactic cavotricuspid isthmus ablation is needed to combine with PV isolation, which may be considered for patients with COPD. However, the recurrence of arrhythmia after first ablation is higher in this type of patients and most of them needed to be performed a second ablation \[[@R13], [@R33], [@R34]\].

Besides, AF will influence the drug treatment of COPD. Beta-adrenergic agonist and theophylline are usually used in the acute exacerbation of COPD, which can accelerate the ventricular rate in AF patients and might deteriorate the circulation stability. Salbutamol can increased heart rate, a strong predictor of AF progression \[[@R35]\]. The 2016 ESC guideline had clearly figured out that non-selective beta-blockers, propafenone and adenosine should be used with caution in patients with significant bronchospasm. Among AF patients with COPD beta-1 selective blockers like bisoprolol, metoprolol, are safe \[[@R36]\]. Amiodarone was the most widely used among all the antiarrhythmic drugs in the persist AF \[[@R37]\]. Antiarrhythmic drugs used as rhythm or rate control agents in the treatment of AF have been associated with a reduction in cardiovascular but not in all-cause mortality, which may seem reasonable considering their mode of action.

As for the predictor of the successful electrical cardioversion, the absence of COPD, chronic heart failure, obstructive sleep apnea syndrome (OSAS), valvular disease, higher HATCH scores, larger left atrial diameter, lower ejection fraction(EF) and advanced ages remained significant \[[@R17]\].

CONCLUSIONS {#s5}
===========

AF progression and recurrence in patients with COPD are of higher risks for mortality, stroke and MACE. COPD is an independent risk for AF progression and recurrence. COPD patients with AF carry a worse prognosis than those in SR. Therefore, to maintain SR long-term may help to reduce the negative impact of AF in COPD patients with effective rhythm control treatments.

Limitations {#s5_1}
-----------

This study presents the following limitations. First, the present studies include all the treatment of AF including the catheter ablation, electrical cardioversion and drug cardioversion to evaluate the outcome. However, the choose of therapy is based on the overall evaluation of the patients' physical condition and most of the medication-refractory AF will undergo catheter ablation, which might cause selection bias. Additionally, most patients are not only combined with COPD. Patients with AF and COPD have more traditional cardiovascular risk factors (diabetes mellitus, hypertension, aging, heart failure, impaired renal function, obesity, larger LA diameter), all of which are important parameters that predict recurrence and progression. These complicated clinical features may weaken the predictive effects of comorbidity COPD on progression and recurrence. Thirdly, in order to include the largest dates, almost all of them are observed studies and prospective studies instead of random control trials. There might be some selection bias.
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